NCCN publishes new recommendations for treating children with brain tumors

NeOnc Technologies receives California Investment Forum’s Breakthrough Medical Technology Achievement Award

NeOnc Technologies Holdings Inc., a clinical-stage biopharmaceutical company, has received the Breakthrough Medical Technology Achievement Award from the California Investment Forum for its innovations in medical technology related to the treatment of brain and central nervous system diseases.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Serotonin-producing neurons regulate malignancy in ependymoma brain tumors

A study published in Nature reveals the functional relevance of tumor-neuron interactions that regulate the growth of ependymoma brain tumors.

August 02, 2024

Vol.50 No.31

Clinical Roundup

AI system identifies genes that can convert brain cancer cells into functioning immune cells in mice

In an innovative new study of glioblastoma, scientists used artificial intelligence to reprogram cancer cells, converting them into dendritic cells, which can identify cancer cells and direct other immune cells to kill them.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Socioeconomic status affects survival of children with cancer

Socioeconomic factors can influence the diagnosis and treatment of children in Texas with malignant solid tumors, increasing the risk of the cancer’s spread and lowering the five-year survival rate, according to researchers at UT Southwestern Medical Center.

July 26, 2024

Vol.50 No.30

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.

Unexpected role of OTX2 drives aggressive medulloblastoma

Researchers at Baylor College of Medicine, Texas Children’s Hospital, the University of Manitoba, and collaborating institutions revealed an unexpected way in which the protein OTX2 drives the progression of medulloblastoma—the most common aggressive childhood brain cancer.

July 19, 2024

Vol.50 No.29

NCCN publishes new recommendations for treating children with brain tumors

YOU MAY BE INTERESTED IN

NeOnc Technologies receives California Investment Forum’s Breakthrough Medical Technology Achievement Award

Serotonin-producing neurons regulate malignancy in ependymoma brain tumors

AI system identifies genes that can convert brain cancer cells into functioning immune cells in mice

Socioeconomic status affects survival of children with cancer

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Unexpected role of OTX2 drives aggressive medulloblastoma

Renew today!

Subscriber content

Login

NCCN publishes new recommendations for treating children with brain tumors

YOU MAY BE INTERESTED IN

NeOnc Technologies receives California Investment Forum’s Breakthrough Medical Technology Achievement Award

Serotonin-producing neurons regulate malignancy in ependymoma brain tumors

AI system identifies genes that can convert brain cancer cells into functioning immune cells in mice

Socioeconomic status affects survival of children with cancer

Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Unexpected role of OTX2 drives aggressive medulloblastoma

Login

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”